1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €62.42 (+106.01%). The median is €60.69 (+100.30%).
| Buy |
6 |
| Hold |
1 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | June 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | 0 | 100.00% |
| Net profit | -30.22m | 61.78% |
| EBITDA | -28.14m | 56.07% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €486.1m |
Number of shares | 15.8m |
52-week high/low | €37.85 - €13.81 |
| Dividends | No |
Beta | 1.96 |
P/E ratio | -6.44 |
PEG ratio | 0.37 |
P/B ratio | 3.69 |
P/S ratio | 0.00 |
Company profile
Neurogene Inc. entwickelt lebensverändernde genetische Medikamente für Patienten und deren Familien, die von neurologischen Krankheiten betroffen sind. Zu den Produktkandidaten des Unternehmens gehören NGN-401, eine AAV9-Gentherapie zur Behandlung des Rett-Syndroms, und NGN-101 zur Behandlung der neuronalen Ceroid-Lipofuszinose-Subtyp-5-Lattenkrankheit. Der Hauptsitz des Unternehmens befindet sich in New York, New York.
| Name | NEUROGENE INC |
| CEO | Rachel L. McMinn |
| Headquarters | New York City,
ny USA |
| Website | |
| Industry | Chemicals |
| IPO | 07/03/2014 |
| Employees | 131 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | NGNE |
Frankfurt | UU8.F |
Düsseldorf | UU8.DU |
